Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Korro Bio (KRRO) Equity Average (2019 - 2025)

Korro Bio's Equity Average history spans 7 years, with the latest figure at $75.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 55.75% year-over-year to $75.2 million, compared with a TTM value of $75.2 million through Dec 2025, down 55.75%, and an annual FY2025 reading of $105.9 million, down 35.87% over the prior year.
  • Equity Average for Q4 2025 was $75.2 million at Korro Bio, down from $107.1 million in the prior quarter.
  • The five-year high for Equity Average was $188.9 million in Q3 2024, with the low at -$144.3 million in Q3 2023.
  • Average Equity Average over 5 years is $78.4 million, with a median of $105.7 million recorded in 2022.
  • Year-over-year, Equity Average plummeted 408.34% in 2023 and then surged 1941.83% in 2024.
  • Tracing KRRO's Equity Average over 5 years: stood at $52.5 million in 2021, then crashed by 116.26% to -$8.5 million in 2022, then skyrocketed by 197.63% to $8.3 million in 2023, then surged by 1941.83% to $170.0 million in 2024, then plummeted by 55.75% to $75.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Equity Average are $75.2 million (Q4 2025), $107.1 million (Q3 2025), and $127.0 million (Q2 2025).